1Nestler EJ, Hyman SE, Malenka RC. Catecholamines. In:Nestler Hyman SE, Malenka RC, editors, Molecular neuropharmacology: a foundation for clinical neuroscience.Beijing: People's Medical Publishing House and McGraw-Hill; 2001. p 182.
2Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K. Role of protein phosphatase-2A and -1 in the regulation of GSK-3,cdk5 and cdc 2 and the phosphorylation of tau in rat forebrain.FEBS. Lett 2000; 485: 87-93.
3Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K. Inhibition of PP-2A upregulates CaMKII in rat forebrain and induces hyperphosphorylation of tau at Ser262/356. FEBS Lett 2001;.490: 15-22.
4Greengard P. The neurobiology of slow synaptic transmission. Science 2001; 294: 1024-1030.
5Winder DG, Sweatt JD. Roles of serine/threonine phosphatases in hippocampal synaptic plasticity. Nat Rev Neurosci 2001; 2: 461-474.
6Bauman AL, Apparsundaram S, Ramamoorthy S, Wadzinski BE, Vaughan RA, Blakely RD. Cocaine and antidepressantsensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A. J Neurosci 2000; 20:.7571-7578.
7Nishi A, Bibb J, Snyder GL, Higashi H, Naim AC, Greengard P. Amplification of dopaminergic signaling by a positive feedback loop. Proc Natl Acad Sci USA 2000; 97: 12840-12845.
8Liu S J, Wang JZ. Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin. Acta Pharmacol Sin 2002; 22: 183-187.
9Andorfer CA, Davies P. PKA phosphorylations on tau:developmental studies in the mouse. Dev Neurosci 2000; 22:303-304.
10Horsburgh K, Saitoh T. Altered signal transduction in Alzheimer's disease. In: Terry RD, Katzman R, Bick KL,editors. Alzheimer disease. New York: Raven Press Ltd;1994. p 387-404.
